What went wrong with a rabies vaccine batch?

What Went Wrong with a Rabies Vaccine Batch? — UPSC Study Note

1. At a Glance

• A counterfeit batch of India's widely used human anti-rabies vaccine Abhayrab (manufactured by Indian Immunologicals Limited, IIL) was found in circulation in India from at least November 1, 2023. [S1]
• Both the U.S. Centers for Disease Control and Prevention (CDC) and Australia's Technical Advisory Group on Immunisation (ATAGI) issued international health warnings after rabies deaths were recorded among travellers returning from India. [S1]
• Critically important for UPSC: This episode exposes gaps in drug quality surveillance, supply chain integrity, and National Regulatory Authority (NRA) oversight — all core GS-II/GS-III themes.
• Rabies is virtually 100% fatal once clinical symptoms appear; a counterfeit vaccine during post-exposure prophylaxis (PEP) is, in effect, a death sentence — making this both a public health emergency and a governance failure.

2. Why in the News

• November 25, 2025: CDC issued a formal travel health notice warning that counterfeit Abhayrab was circulating in major Indian cities and could both harm recipients and fail to prevent rabies. [S1]
• Late 2025: ATAGI (Australia) advised all travellers who received Abhayrab in India after November 1, 2023 to treat their vaccination as invalid and restart the full vaccination course. [S1]
• The alerts followed confirmed rabies cases in international travellers who had received what they believed to be valid PEP in India. [S1]
• December 27, 2025: IIL stated the counterfeit batch had been removed from shelves. [S1]

3. Background & Evolution

• Rabies in India: India accounts for approximately 36% of global rabies deaths (~20,000 annually; WHO data) — the highest of any country — primarily from dog bites.
• Abhayrab: A cell-culture-based human anti-rabies vaccine (Purified Vero Cell Rabies Vaccine, PVRV) manufactured by Indian Immunologicals Limited (IIL), a subsidiary of the National Dairy Development Board (NDDB) — a Government of India undertaking.
• Regulation: Under the Drugs and Cosmetics Act, 1940, every vaccine batch in India must be tested and released by the National Control Laboratory (Central Drugs Laboratory, CDL, Kasauli). The CDL holds WHO-Geneva pre-qualification status. [S1]
• Counterfeit start point: The spurious batch entered the market on or after November 1, 2023 — approximately 2 years before the CDC alert. [S1]
• Historical context: India has faced periodic spurious drug scandals (e.g., contaminated eye drops, substandard IV fluids), but a counterfeit life-saving vaccine attracting simultaneous U.S. and Australian government alerts is unprecedented in recent memory.

4. Core Static Facts

5. Multi-Dimensional Analysis

Scientific / Technological

• PVRV vaccines (Purified Vero Cell Rabies Vaccine) are the gold standard for human PEP; any counterfeit lacks the attenuated antigen needed to stimulate neutralising antibody response. [S1]
• The incubation period of rabies (days to years, typically 1–3 months) means victims of counterfeit PEP may not know they are unprotected until it is too late.
• Batch traceability failure: Genuine Abhayrab batches are tested by CDL before release; counterfeit batches bypass this entirely — the problem lies in post-market supply chain infiltration, not pre-release testing. [S1]

Governance / Administrative

• A two-year lag (Nov 2023 → Nov 2025) between estimated market entry of the counterfeit and the CDC/ATAGI alert reveals critical weaknesses in India's pharmacovigilance and adverse event following immunisation (AEFI) reporting systems. [S1]
• CDSCO (the nodal drug regulator under MoH&FW) faced implicit criticism for not detecting the spurious batch earlier through market surveillance.
• India's drug regulation operates on a dual federal structure: Centre (CDSCO) licenses manufacturing; States license retail — creating surveillance gaps at the distribution level.

Legal / Constitutional

• Section 17B, Drugs and Cosmetics Act, 1940: Manufacture/sale of spurious drugs is a cognisable, non-bailable offence punishable with imprisonment up to life (or minimum 10 years) plus fine.
• The episode could invoke product liability under the Consumer Protection Act, 2019 for affected patients.
• Article 21 (Right to Life) jurisprudence obligates the State to ensure access to safe medicines.

Social

• Rabies PEP is predominantly sought by lower-income, rural populations exposed to dog bites — the segment least equipped to verify vaccine authenticity or seek repeat vaccination abroad.
• International travellers (wealthier, with access to home-country health systems) were the ones who triggered the alert — highlighting an equity paradox in surveillance: systemic failure visible only via foreign health authorities.
• Australia's advisory to restart vaccination imposes significant financial and psychological burden on travellers who received counterfeit doses in good faith.

Economic

• IIL, a publicly backed vaccine manufacturer, faces reputational damage even though the counterfeit was not its manufacturing failure — underscoring how brand impersonation harms legitimate producers.
• India's vaccine export credibility (it manufactures ~60% of global vaccines by volume) is at risk if regulatory surveillance is seen as porous.

Ethical / Governance

• The two-year surveillance gap raises accountability questions: Who failed to correlate AEFI reports with a specific vaccine batch? Were whistleblower mechanisms in place?
• Transparency: IIL's December 2025 statement that the batch was "no longer on shelves" came a month after the CDC alert — the timeline of internal knowledge vs. public disclosure is ethically significant. [S1]

6. Recent Developments (Last 12–18 Months)

• November 25, 2025: CDC (U.S.) issued travel notice on counterfeit Abhayrab circulating in major Indian cities. [S1]
• Late November 2025: ATAGI (Australia) advised travellers vaccinated with Abhayrab in India post-November 1, 2023, to consider doses invalid and re-vaccinate. [S1]
• December 27, 2025: IIL Vice-President (Quality Management) Sunil Tiwari publicly confirmed the counterfeit batch was no longer in circulation. [S1]
• January 4, 2026: The Hindu published a detailed explainer ("What went wrong with a rabies vaccine batch?") authored by Bindu Shajan Perappadan, consolidating the CDC warning, ATAGI advisory, and IIL response. [S1]

7. Prelims Hooks

1. Abhayrab is a Purified Vero Cell Rabies Vaccine (PVRV) manufactured by Indian Immunologicals Limited (IIL).
2. IIL is a subsidiary of the National Dairy Development Board (NDDB) — a Government of India undertaking.
3. Every vaccine batch in India must be released by the Central Drugs Laboratory (CDL), Kasauli before market entry.
4. CDL, Kasauli is WHO-Geneva pre-qualified under India's National Regulatory Authority (NRA) framework.
5. The CDC issued its travel notice on November 25, 2025, specifically naming counterfeit Abhayrab.
6. ATAGI (Australian Technical Advisory Group on Immunisation) declared Abhayrab doses administered after November 1, 2023 as potentially invalid.
7. Manufacture/sale of spurious drugs under Section 17B of the Drugs and Cosmetics Act, 1940 carries a minimum 10-year prison sentence.
8. India bears approximately 36% of global rabies deaths annually (WHO estimate).
9. CDSCO (Central Drugs Standard Control Organisation) under the Ministry of Health and Family Welfare is India's apex drug regulator.
10. Rabies is virtually 100% fatal once clinical (encephalitic) symptoms manifest.
11. The WHO-recommended PEP schedule for rabies is 4–5 intramuscular doses over 14–28 days, potentially with Rabies Immunoglobulin (RIG) for severe exposures.
12. The counterfeit problem was first flagged internationally by authorities in Australia and the United States — not India's domestic surveillance system.

8. Mains Relevance

Plausible Mains Question Stems:

1. "The counterfeit Abhayrab rabies vaccine episode exposed systemic gaps in India's post-market drug surveillance framework. Critically examine the regulatory architecture under the Drugs and Cosmetics Act, 1940, and suggest structural reforms." (GS-II)
2. "India manufactures a significant share of the world's vaccines yet faces credibility challenges due to spurious drug circulation. Analyse the dual federal structure of drug regulation as a contributing factor and propose a path forward." (GS-II/GS-III)
3. "Evaluate the ethical obligations of public sector vaccine manufacturers and regulatory bodies when a counterfeit of a life-saving product enters the market." (GS-IV)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Confusing IIL with the counterfeiter: The counterfeit was not manufactured by IIL — it was a third-party spurious product impersonating IIL's brand. IIL's own batch release process (via CDL) was not the failure point.
2. Confusing CDL Kasauli with CDSCO: CDL (Central Drugs Laboratory, Kasauli) is the batch-testing laboratory; CDSCO is the regulatory authority — they are distinct institutions under MoH&FW.
3. Assuming the problem was a manufacturing defect: This was a supply chain / distribution layer failure (counterfeiting), not a lapse in IIL's manufacturing quality management.
4. Wrong parent ministry for IIL: IIL's parent is NDDB (under Ministry of Fisheries, Animal Husbandry & Dairying), not the Ministry of Health — a common trick question.
5. Thinking ATAGI is an Indian body: ATAGI = Australian Technical Advisory Group on Immunisation. The Indian equivalents are NTAGI (National Technical Advisory Group on Immunisation) under MoH&FW.

11. Sources

• [S1] Bindu Shajan Perappadan, "What went wrong with a rabies vaccine batch?" — The Hindu, January 4, 2026 (Sunday edition, Page 8, International Print Edition) — https://www.thehindu.com/todays-paper/2026-01-04/th_international/articleGP8FD3LOQ-12986412.ece — (Tier 4)

Note: Web searches were blocked by domain-access restrictions during this session. This note is grounded entirely in the article content (Tier 4 primary source) supplemented by established WHO/regulatory framework knowledge. All regulatory facts (CDL, CDSCO, Drugs and Cosmetics Act, WHO-PQ) are verifiable at who.int and pib.gov.in.